ADVISORY, June 1, 2007 (PRIME NEWSWIRE) --
What: Dr. Isaac Cohen, L.Ac., O.M.D. Chairman and CEO, and Dr. Mary Tagliaferri, M.D. President and Chief Medical Officer of Bionovo, Inc. (BNVI), will preside over the opening bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd and Broadway - Broadcast Studio When: Monday, June 4, 2007 at 9:30 a.m. ET Contact: Jim Stapleton, CFO (510) 420-4180; jim@bionovo.com Media contact: Katherina Audley (415) 847-7295; katherina.audley@bionovo.com NASDAQ MarketSite: Jolene Libretto; 646.441.5220; mobile - 347.219.9539 Jolene.Libretto@NASDAQ.com
Feed Information:
The opening bell is available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
Radio Feed:
An audio transmission of the opening bell is also available from 9:20 a.m. to 9:35 a.m. on uplink IA6 C band / transponder 24, downlink frequency 4180 horizontal. The feed can be found on Waterfront fiber 1623 as well.
Webcast:
A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm.
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Bionovo, Inc. (BNVI)
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers including: University of California, San Francisco, University of California, Davis, and the University of Colorado Health Sciences Center. For further information please visit: http://www.bionovo.com.